Table 6.
(A) | 01/27–05/27/2020* | 06/03–07.04.2020 | |||
---|---|---|---|---|---|
Position | Location | Mutation | Count | Count | Incidence |
241nt | 5´UTR | CG → TG | 82/99 | 95/98 | Prevalent |
noneffective | |||||
2,292nt | nsp2 | AG → CG | 0/99 | 22/98 | Unique |
CAG (Glutamine) → CCG (Proline) | |||||
2,836nt | nsp3 | CT → TT | 23/99 | 44/98 | Unique |
noneffective | |||||
3,037nt | CT → TT | 81/99 | 96/98 | Prevalent | |
noneffective | |||||
3,634nt | CA → TA | 8/99 | 17/98 | ZA | |
noneffective | |||||
4,084nt | CA → TA | 12/99 | 1/98 | ZA | |
noneffective | |||||
4,300nt | GC → TC | 0/99 | 16/98 | Unique | |
noneffective | |||||
6,312nt | CA → AA | 10/99 | 0/98 | US | |
ACA (Threonine) → AAA (Lysine) | |||||
11,083nt | nsp6 | GT → TT | 13/99 | 0/98 | BR,CN,DE, |
TTGTAT (Leucine Tyrosine) → TTT (Phenylalanine) | ES,FR,US, | ||||
ZA | |||||
14,408nt | RNA‐dependent RNA polymerase | CT → TT | 80/99 | 91/98 | Prevalent |
CCT (Proline) → CTT (Leucine) | |||||
15,324nt | CA → TA | 7/99 | 18/98 | B,C,G,F | |
noneffective | |||||
16,512nt | Helicase | AT → GT | 0/99 | 11/98 | Unique |
noneffective | |||||
18,568nt | 3´‐ to ‐ 5´exonuclease | CT → TT | 0/99 | 22/98 | Unique |
CTC (Leucine) → TTC (Phenylalanine) | |||||
18,877nt | CT → TT | 45/99 | 51/98 | BR,DE,ES, | |
noneffective | FR,US | ||||
19,154nt | CA → TA | 0/99 | 12/98 | Unique | |
ACA (Threonine) → ATA (Isoleucine) | |||||
21,724nt | Spike glycoprotein | GT → TT | 6/99 | 23/98 | RU |
TTGTTC (Leucine Phenylalanine) → TTTTTC (Phenylalanine Phenylalanine) | |||||
22,444nt | CC → TC | 26/99 | 48/98 | US | |
noneffective | |||||
23,403nt | AT → GT | 80/99 | 96/98 | Prevalent | |
GAT (Aspartic Acid) → GGT (Glycine) | |||||
23,929nt | CA → TA | 10/99 | 0/98 | FR,RU,US | |
noneffective | |||||
25,563nt | ORF3a protein | GA → TA | 43/99 | 51/98 | Prevalent |
CAGAGC (Glutamine Serine) → CATAGC (Histidine Serine) | |||||
26,735nt | Membrane glycoprotein | CA → TA | 39/99 | 49/98 | DE,ES,FR, |
noneffective | US | ||||
28,311nt | Nucleocapsid phosphoprotein | CC → TC | 10/99 | 0/98 | Unique |
CCC (Proline) → CTC (Leucine) | |||||
28,854nt | CA → TA | 29/99 | 41/98 | CN,DE,ES, | |
TCA (Serine) → TTA (Leucine) | FR,RU,US, | ||||
ZA |
(B) | 01/19/2020–01/20/2021 | |||
---|---|---|---|---|
Position | Location | Mutation | Total Count | Percentage |
241nt | 5´UTR | C → T | 2,816 | 85.93 |
313nt | ORF1ab polyprotein → leader protein | C → T | 944 | 28.81 |
1,947nt | nsp2 | T → C | 100 | 3.05 |
2,292nt | A → C | 73 | 2.23 | |
2,836nt | nsp3 | C → T | 281 | 8.57 |
3,037nt | C → T | 2,824 | 86.18 | |
3,634nt | C → T | 283 | 8.64 | |
4,300nt | G → T | 70 | 2.14 | |
4,354nt | G → A | 227 | 6.93 | |
4,372nt | A → G | 72 | 2.2 | |
5,700nt | C → A | 949 | 28.96 | |
6,312nt | C → A | 302 | 9.22 | |
6,573nt | C → T | 228 | 6.96 | |
8,782nt | nsp4 | C → T | 74 | 2.26 |
8,917nt | C → T | 122 | 3.72 | |
9,693nt | C → T | 156 | 4.76 | |
11,083nt | nsp6 | G → T | 369 | 11.26 |
13,730nt | RNA‐dependent RNA polymerase | C → T | 332 | 10.13 |
14,408nt | C → T | 2,768 | 84.47 | |
15,324nt | C → T | 285 | 8.7 | |
16,626nt | Helicase | C → T | 143 | 4.36 |
18,568nt | 3'‐to‐5' exonuclease | C → T | 71 | 2.17 |
18,877nt | C → T | 654 | 19.96 | |
19,524nt | C → T | 69 | 2.11 | |
21,550nt | 2'‐O‐ribose methyltransferase | A → C | 115 | 3.51 |
21,551nt | A → T | 112 | 3.42 | |
21,724nt | Spike glycoprotein | G → T | 109 | 3.33 |
22,444nt | C → T | 507 | 15.47 | |
22,468nt | G → T | 76 | 2.32 | |
23,403nt | A → G | 2,832 | 86.42 | |
23,929nt | C → T | 298 | 9.09 | |
25,528nt | ORF3a | C → T | 222 | 6.77 |
25,563nt | G → T | 652 | 19.9 | |
26,735nt | Membrane glycoprotein | C → T | 654 | 19.96 |
27,384nt | ORF6 | T → C | 77 | 2.35 |
28,144nt | ORF8 | T → C | 73 | 2.23 |
28,311nt | Nucleocapsid phosphoprotein | C → T | 299 | 9.12 |
28,854nt | C → T | 541 | 16.51 | |
28,878nt | G → A | 70 | 2.14 | |
28,881nt | G → A | 1,434 | 43.76 | |
28,882nt | G → A | 1,430 | 43.64 | |
28,883nt | G → C | 1,430 | 43.64 | |
29,474nt | G → T | 72 | 2.2 | |
29,750nt | 3´UTR | C → T | 74 | 2.26 |
29,868nt | at downstream region of ORF10 | G → A | 351 | 10.71 |
29,870nt | C → A | 154 | 4.7 |
The Table presents characteristics of SARS‐CoV‐2 mutants from isolates collected in the Indian population. For Table design, see legend to Table 5.